Squarepoint
ACET icon

Squarepoint’s Adicet Bio ACET Stock Holding History

Squarepoint’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$132K Buy
+15,254
New +$120K ﹤0.01% 4156
2026
Q1 		– Sell
-55,723
Closed -$469K – 4193
2025
Q4 		$469K Buy
55,723
+52,821
+1,820% +$584K ﹤0.01% 3268
2025
Q3 		$37.6K Buy
+2,902
New +$34.2K ﹤0.01% 4250
2025
Q2 		– Sell
-723
Closed -$8.73K – 4429
2025
Q1 		$8.73K Sell
723
-10,799
-94% -$154K ﹤0.01% 4461
2024
Q4 		$177K Buy
+11,522
New +$217K ﹤0.01% 4513
2024
Q3 		– Sell
-22,639
Closed -$438K – 4046
2024
Q2 		$438K Buy
22,639
+21,839
+2,730% +$585K ﹤0.01% 3179
2024
Q1 		$30.1K Sell
800
-965
-55% -$39.9K ﹤0.01% 3903
2023
Q4 		$53.4K Buy
1,765
+114
+7% +$2.49K ﹤0.01% 3841
2023
Q3 		$36.2K Buy
1,651
+941
+133% +$33.2K ﹤0.01% 3663
2023
Q2 		$27.6K Sell
710
-264
-27% -$23.3K ﹤0.01% 3477
2023
Q1 		$89.8K Sell
974
-40
-4% -$5.02K ﹤0.01% 2987
2022
Q4 		$145K Buy
+1,014
New +$253K ﹤0.01% 2882
2020
Q3 		– Sell
-545
Closed -$131K – 2442
2020
Q2 		$131K Buy
+545
New +$107K ﹤0.01% 1951

Other funds holding ACET

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Squarepoint's ACET Position: Q2 2026 in Review

Squarepoint opened a new position in Adicet Bio (ACET) in Q2 2026: 15,254 shares worth $132K. The stake represents ﹤0.01% of the portfolio and ranks #4156 among its holdings. This is a return to the name: Squarepoint previously reported a position in ACET as recently as Q4 2025.

Squarepoint first reported a position in ACET in Q2 2020 and has held it in 13 quarters since. The position peaked at $469K in Q4 2025. 56 funds tracked by Wall St. Rank hold ACET as of Q2 2026.

  • Squarepoint held 15,254 shares of Adicet Bio worth $132K as of Q2 2026.
  • Adicet Bio was a new Squarepoint position in Q2 2026.
  • Adicet Bio made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #4156 holding.
  • Squarepoint first reported a position in Adicet Bio in Q2 2020 and has held it in 13 quarters since.
  • Squarepoint's Adicet Bio position peaked at $469K in Q4 2025.
  • 56 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.